News & Events

17 01, 2023

Scientists develop novel mRNA delivery method using extracellular vesicles

2025-06-24T13:58:50+00:00

In the study, published in Nature Biomedical Engineering, researchers from MD Anderson Cancer Center use EV-encapsulated mRNA to initiate and sustain collagen production for several months in the cells of photoaged skin in laboratory models. It is the first therapy to demonstrate this ability and represents a proof-of-concept for deploying the EV mRNA therapy...

Scientists develop novel mRNA delivery method using extracellular vesicles2025-06-24T13:58:50+00:00
13 12, 2022

ASGCT Members Provide Recommendations During FDA Liaison Meeting

2025-06-24T14:24:36+00:00

ASGCT held its fifth annual liaison meeting with FDA CBER’s Office of Tissues and Advanced Therapies (OTAT) on Nov. 14, 2022. A group of Society leaders and members gave two presentations to FDA on significant topics in the field, followed by a presentation from FDA. Dr. Keith Wonnacott, ASGCT’s Regulatory Affairs Committee Chair, chaired the meeting and moderated discussion...

ASGCT Members Provide Recommendations During FDA Liaison Meeting2025-06-24T14:24:36+00:00
6 12, 2022

CG Oncology advancing clinical-stage urologic oncology immunotherapy pipeline

2025-06-24T14:35:10+00:00

Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...

CG Oncology advancing clinical-stage urologic oncology immunotherapy pipeline2025-06-24T14:35:10+00:00
28 11, 2022

Gene Therapy Analytical Development Summit – 2022

2025-06-24T14:26:29+00:00

Avance offers a broad range of assay development services, including assay design, assay validation, sample testing, and technology transfer under GLP compliance to support IND-enabling and clinical studies. With decades of experience helping gene and cell therapy companies, Avance Biosciences™ has the...

Gene Therapy Analytical Development Summit – 20222025-06-24T14:26:29+00:00
22 11, 2022

Quantification of On/Off-Target Gene Editing

2025-06-24T14:35:30+00:00

Quantitative analysis of gene editing is now an essential step in getting regulatory approval of gene editing-based therapies. But designing and validating assays for on/off-target editing analysis and building an internal team to perform them can be costly and inefficient...

Quantification of On/Off-Target Gene Editing2025-06-24T14:35:30+00:00
9 11, 2022

CHOP Study Offers Proof of Concept for Treating Pediatric Brain Tumors with Immunotherapy

2025-06-24T14:35:37+00:00

Although immunotherapy has revolutionized the treatment of many blood cancers, the field has encountered challenges developing similar treatments for solid tumors. When it comes to pediatric brain tumors, which are the leading cause of cancer death in children, challenges include...

CHOP Study Offers Proof of Concept for Treating Pediatric Brain Tumors with Immunotherapy2025-06-24T14:35:37+00:00
1 11, 2022

Remarkable results from CAR-T cell therapy for lupus

2025-06-24T14:35:43+00:00

A recent study has shown remarkable results from compassionate use of CAR-T cell therapy to treat severe lupus in five patients in whom multiple other treatments had previously failed. CAR-T cell therapy involves genetically engineering T cells, a type of immune cell, so that they respond to a prespecified molecular marker, or antigen. This means they mount an immune response against cells with the chosen antigen...

Remarkable results from CAR-T cell therapy for lupus2025-06-24T14:35:43+00:00
26 10, 2022

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis

2025-06-24T14:35:54+00:00

Company files its first Investigational New Drug application for its lead program KYV-101, a novel fully human CD19 CAR T-cell therapy, for the treatment of lupus nephritis. Kyverna’s therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate...

Kyverna Therapeutics Submits IND for Novel CAR T-Cell Therapy to Treat Lupus Nephritis2025-06-24T14:35:54+00:00
18 10, 2022

A report on the state of the cell and gene therapy industry

2025-06-24T14:36:31+00:00

Twice a year, the Alliance for Regenerative Medicine (ARM) surveys the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to their members, their stakeholders, and the public at large. While external conditions ebb and flow, the sector’s progress — in clinical milestones, regulatory developments, and patient impact — steadily advances...

A report on the state of the cell and gene therapy industry2025-06-24T14:36:31+00:00
11 10, 2022

Cell & Gene Meeting on the Mesa – 2022

2025-06-24T14:26:29+00:00

Avance offers a broad range of assay development services, including assay design, assay validation, sample testing, and technology transfer under GLP compliance to support IND-enabling and clinical studies. With decades of experience helping gene and cell therapy companies, Avance Biosciences™ has the...

Cell & Gene Meeting on the Mesa – 20222025-06-24T14:26:29+00:00
Go to Top